National Institute Of Allergy And Infectious Diseases (niaid)
Clinical trials sponsored by National Institute Of Allergy And Infectious Diseases (niaid), explained in plain language.
-
Personalized TB treatment could shorten recovery time
⭐️ CURE ⭐️ Not yet recruitingThis study tests whether tuberculosis (TB) treatment can be tailored to each person's risk of a poor outcome. About 900 adults with drug-sensitive TB will be grouped as lower-risk or higher-risk. Lower-risk participants may get a shorter treatment course, while higher-risk partic…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
Nasal spray vaccine aims to stop COVID-19 at the source
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new type of COVID-19 booster vaccine given as a nasal spray. The vaccine uses a weakened live virus to train the immune system, potentially offering stronger protection in the nose and throat where the virus enters. Researchers are enrolling 80 healthy adults a…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can a nanoparticle vaccine train the body to fight HIV?
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial is testing whether experimental HIV vaccines can safely teach the immune system to recognize and fight the virus. Healthy adults without HIV will receive a protein nanoparticle vaccine, followed by a booster—either another protein nanoparticle or an mRNA va…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
New mRNA vaccine aims to outsmart flu by targeting its hidden parts
⭐️ VACCINE ⭐️ Not yet recruitingThis Phase 1 trial tests experimental mRNA vaccines designed to protect against many types of influenza A by targeting a stable part of the virus. Healthy adults aged 18 to 59 receive one or two doses of the vaccine candidates, alone or in combination. The study checks for side e…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
Engineered yeast pill takes on superbug c. diff in first human trial
Disease control Not yet recruitingThis early-stage trial tests an oral capsule containing a genetically modified probiotic yeast designed to neutralize toxins produced by C. diff bacteria. The study first evaluates safety in healthy adults, then in people at risk for recurrent C. diff infection. Participants take…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can two antibodies free HIV patients from daily pills? early trial launches
Disease control Not yet recruitingThis early-stage study tests whether two lab-made antibodies can help people with HIV control the virus after stopping their regular antiretroviral therapy. The 40 participants all started HIV treatment very early after infection. Researchers will monitor safety and see if the an…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple steroid course save lives in severe respiratory infections?
Disease control Not yet recruitingThis study tests whether giving a 7-day course of corticosteroids (like prednisolone) to hospitalized adults with severe respiratory infections and low oxygen levels can reduce deaths and the need for breathing machines. About 3,000 participants will be randomly assigned to recei…
Phase: PHASE4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Modified pork could revolutionize Alpha-Gal allergy testing
Diagnosis Not yet recruitingThis study tests whether specially modified pork (alpha-gal knockout) causes fewer allergic reactions than regular pork in people with alpha-gal syndrome. Each of the 160 participants will eat both types of pork on different days to see which one is safer for diagnosis. The goal …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
New daily pill could shield kids from TB
Prevention Not yet recruitingThis study tests a 28-day daily combination of two drugs, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13. About 144 children, some with HIV and some without, will join to find the right dose and check for side effects. The goal is to see if this shor…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 13:07 UTC
-
Can a simple test predict peanut allergy reactions?
Knowledge-focused Not yet recruitingThis study aims to find biomarkers—signs in the body—that can tell if a child will have an allergic reaction to peanut during a feeding test. It will involve 500 children aged 1 to 17 who are suspected of having a peanut allergy. No treatment is given; the goal is to better under…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC